ASCO 2021: Summary Overview and Prospects 17 | Major Progress in Research on Hepatocellular Carcinoma (Phase 2)

The annual meeting of the American Society of Clinical Oncology ( ASCO ) will be held from June 4 to 8, 2021.

The annual meeting of the American Society of Clinical Oncology ( ASCO ) will be held from June 4 to 8, 2021.

Hepatocellular carcinoma topic summary

Hepatocellular carcinoma topic summary

ASCO 2021: Blockbuster Study of Hepatocellular Carcinoma (Phase 1)

ASCO 2021: Blockbuster Study of Hepatocellular Carcinoma (Phase 1) ASCO 2021: Blockbuster Study of Hepatocellular Carcinoma (Phase 1)

1.

1 , Chinese hepatocellular carcinoma ( HCC ) in patients with adjuvant therapy decision-making factors of 1 , Chinese hepatocellular carcinoma ( HCC ) in patients with secondary factors that influence treatment decisions 1, Chinese hepatocellular carcinoma (HCC) in patients with secondary factors that influence treatment decisions

This study aims to understand the decision-making factors of patients with adjuvant treatment after hepatocellular carcinoma ( HCC ) resection in China .

This study aims to understand the decision-making factors of patients with adjuvant treatment after hepatocellular carcinoma ( HCC ) resection in China .

The study used a questionnaire ( https://pro.

The questionnaire survey covers three aspects: the decision-making of adjuvant treatment, the choice of treatment plan, and the influence of the risk of recurrence on the willingness to receive adjuvant treatment, and it is scored from 1 (no impact) to 7 (high impact).

The results showed that a total of 2220 valid answers were collected .

Most interviewees ( 75% most interviewees ( 75% most interviewees (75% ) think that doctors are decision-makers who use adjuvant treatment and choose treatment options.

Therefore, most patients receive adjuvant therapy, the most common of which are systemic therapy and TACE .

For details, see: Factors influencing adjuvant treatment decision making among Chinese patients with hepatocellular carcinoma (HCC): Results of a patient survey.

2.

TACE and lenvatinib have been proven to prolong the overall survival of patients with unresectable HCC .

Researchers from receiving the 2018 Nian 11 months to 2020 Nian 6 months, 79 patients received TACE and lenvatinib combination therapy, follow-up Chaoguo 2 months, and was divided into early combination therapy group (in the first TACE plus before or after Use lenvatinib ) and the advanced combination therapy group ( add lenvatinib after at least two TACE operations ).

，48 HCC，9.

，，，lenvatinibTACEHCClenvatinibTACEHCClenvatinibTACEHCC。。。mPFS，。

：When will it be better? Lenvatinib combined with TACE for unresectable hepatocellular carcinoma: A retrospective analysis of real-world evidence in China.

：When will it be better? Lenvatinib combined with TACE for unresectable hepatocellular carcinoma: A retrospective analysis of real-world evidence in China.
When will it be better? Lenvatinib combined with TACE for unresectable hepatocellular carcinoma: A retrospective analysis of real-world evidence in China.

3，OPTIMIS： (TACE)

3，OPTIMIS： (TACE) 3，OPTIMIS： (TACE) 3，OPTIMIS：OPTIMIS (TACE)

TACEHCC，。，TACE，。，TACE，。OPTIMIS，TACE。

TACEHCC，。，TACE，。，TACE，。OPTIMIS，TACE。

OPTIMIS，1670HCC，977TACE。，CTCAE ，（AST）、（ALT）、、（INR）。

OPTIMIS，1670HCC，977TACE。，CTCAE ，（AST）、（ALT）、、（INR）。

，BCLC CB，。7749% vs 43%。，TACE53% vs 44%。

，BCLC CB，。7749% vs 43%。，TACE53% vs 44%。BCLC CB，。7749% vs 43%。，TACE53% vs 44%。BCLC CB，。7749% vs 43%。，TACE53% vs 44%。

，HCCTACE。，TACETACE。

，HCCTACE。，TACETACE。TACETACE。TACETACE。

：Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE.

：Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE.
Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS—An international observational study assessing the use of sorafenib after TACE.